SPY303.53+4.45 1.49%
DIA255.77+5.52 2.21%
IXIC9,412.36+72.14 0.77%

JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $55

JP Morgan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $50 to $55.

Benzinga · 05/08/2020 16:00

JP Morgan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $50 to $55.